a-ads798

Search This Blog

nativeadstera

aads970+250

729adst

798+90yilix

admetex 790+90

ad2bitcoin 728+90

zerads 728+90

aads468+60

zerads 468+60

admetex 460+60

aadsadaptabl

mob ylix

468+60asdster

468+60yilix

aads referal

ad2bit460+60

 


1. a 2. a 3. a 4. a 5. d 6. c 7. 1(d), 2(c), 3(a), 4(b)

8. a. money, material, machine

b. prototype, pilot-plant

c. laboratory

d. scale-up

e. calibration, QA QC activities, labelling.

General Considerations and Pilot-Plant Considerations for Different Dosage Forms 9

2.1 GENERAL CONSIDERATIONS (Fig. 2.3)

General consideration includes the following points to be kept in mind while planning

for scale-up.

2.1.1 Reporting Responsibilities (Fig. 2.1)

There should be adequate records and reporting arrangements to make the transfer of

products from laboratory-scale to a commercial-scale smooth. The transfer is a

multidisciplinary approach as it includes pilot-plant group and other groups like R&D,

processing, engineering, quality assurance, regulatory, marketing, etc. There should

be good communication and relationship between pilot-plant groups and other groups.

R&D group should be with separate staffing. Production department can be under

formulator and formulator can provide support even after the transition of production

has been completed.

2.1.2 Personnel Requirement

It is very important for the smooth transfer of products (from laboratory-scale to pilotplant and then to commercial-scale) to have well-qualified staff. They should have

good knowledge about pharmacy and pharmaceutical industry. Those employed for

9

General Considerations and

Pilot-Plant Considerations for

Different Dosage Forms

2

No comments:

Post a Comment

اكتب تعليق حول الموضوع

728x90'ads

Search This Blog